Abstract:ABSTRACT Chronic hepatitis B virus (HBV) infection is a global public health problem. Although the currently approved medications can reliably reduce the viral load and prevent the progression of liver diseases, they fail to cure the viral infection. In an effort toward discovery of novel antiviral agents against HBV, a group of benzamide (BA) derivatives that significantly reduced the amount of cytoplasmic HBV DNA were discovered. The initial lead optimization efforts identified two BA derivatives with improved antiviral activity for further mechanistic studies. Interestingly, similar to our previously reported sulfamoylbenzamides (SBAs), the BAs promote the formation of empty capsids through specific interaction with HBV core protein but not other viral and host cellular components. Genetic evidence suggested that both SBAs and BAs inhibited HBV nucleocapsid assembly by binding to the heteroaryldihydropyrimidine (HAP) pocket between core protein dimer-dimer interfaces. However, unlike SBAs, BA compounds uniquely induced the formation of empty capsids that migrated more slowly in native agarose gel electrophoresis from A36V mutant than from the wild-type core protein. Moreover, we showed that the assembly of chimeric capsids from wild-type and drug-resistant core proteins was susceptible to multiple capsid assembly modulators. Hence, HBV core protein is a dominant antiviral target that may suppress the selection of drug-resistant viruses during core protein-targeting antiviral therapy. Our studies thus indicate that BAs are a chemically and mechanistically unique type of HBV capsid assembly modulators and warranted for further development as antiviral agents against HBV. IMPORTANCE HBV core protein plays essential roles in many steps of the viral replication cycle. In addition to packaging viral pregenomic RNA (pgRNA) and DNA polymerase complex into nucleocapsids for reverse transcriptional DNA replication to take place, the core protein dimers, existing in several different quaternary structures in infected hepatocytes, participate in and regulate HBV virion assembly, capsid uncoating, and covalently closed circular DNA (cccDNA) formation. It is anticipated that small molecular core protein assembly modulators may disrupt one or multiple steps of HBV replication, depending on their interaction with the distinct quaternary structures of core protein. The discovery of novel core protein-targeting antivirals, such as benzamide derivatives reported here, and investigation of their antiviral mechanism may lead to the identification of antiviral therapeutics for the cure of chronic hepatitis B.

The Novel Compound Z060228 Inhibits Assembly of the HBV Capsid.

Discovery of 5-Alkyl-2-pyrazol-oxazolidin-4-one Derivatives As Novel Hepatitis B Virus Capsid Assembly Modulators

A novel phthalazinone derivative as a capsid assembly modulator inhibits hepatitis B virus expression

Inhibition of Hepatitis B Virus Replication by Bay 41-4109 and Its Association with Nucleocapsid Disassembly.

Novel Hepatitis B Virus Capsid-Targeting Antiviral That Aggregates Core Particles and Inhibits Nuclear Entry of Viral Cores

A Novel Hepatitis B Virus Capsid Assembly Modulator QL-007 Inhibits HBV Replication and Infection Through Altering Capsid Assembly.

A Novel Pyridazinone Derivative Inhibits Hepatitis B Virus Replication by Inducing Genome-Free Capsid Formation

2,4-Diaryl-4,6,7,8-tetrahydroquinazolin-5(1h)-one Derivatives As Anti-Hbv Agents Targeting at Capsid Assembly

Design, synthesis and anti-HBV activity study of novel HBV capsid assembly modulators

Structure-Based Discovery of <i>N</i>-Sulfonylpiperidine-3-Carboxamides as Novel Capsid Assembly Modulators for Potent Inhibition of HBV Replication

Conformationally Constrained Isoquinolinones as Orally Efficacious Hepatitis B Capsid Assembly Modulators

Molecular Mechanisms of Tetrahydropyrrolo[1,2-C]pyrimidines As HBV Capsid Assembly Inhibitors.

Bay 41-4109 Interacts with HBV Capsid/capsid Proteins and Affects the Assembly of HBV

Review Of Small Synthetic Molecules Targeting Hbv Capsid Assembly

Discovery of Carboxyl-Containing Heteroaryldihydropyrimidine Derivatives As Novel HBV Capsid Assembly Modulators with Significantly Improved Metabolic Stability

Identification of Factors Promoting HBV Capsid Self-Assembly by Assembly-Promoting Antivirals.

Optimization and Synthesis of Pyridazinone Derivatives As Novel Inhibitors of Hepatitis B Virus by Inducing Genome-free Capsid Formation

Effect of a Hepatitis B Virus Inhibitor, NZ-4, on Capsid Formation.

Development of Benzimidazole-Based Compounds As Novel Capsid Assembly Modulators for the Treatment of HBV Infection

Design and synthesis of aminothiazole based Hepatitis B Virus (HBV) capsid inhibitors

Discovery and Mechanistic Study of Benzamide Derivatives That Modulate Hepatitis B Virus Capsid Assembly